Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4833-4837

  Morata, Laura ^a   Cobos Trigueros, Nazaret ^a   Mart́inez, José A ^a   Soriano, Álex ^a   Almela, Manel ^a   Marco, Francesc ^a   Sterzik, Holguer ^b   Núñez, Raquel ^a   Hernández, Cristina ^a   Mensa, José ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BILIARY TRACT INFECTION; BONE INFECTION; CATHETER INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMPIRICISM; FEMALE; GRAM NEGATIVE SEPSIS; HIGH RISK POPULATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INAPPROPRIATE PRESCRIBING; INFECTION SENSITIVITY; INFECTIOUS ARTHRITIS; INTRAVASCULAR CATHETER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STEROID THERAPY; URINARY CATHETER; URINARY TRACT INFECTION;

ADULT; AGED; AMIKACIN; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; ODDS RATIO; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84865432568     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00750-12     Document Type: Article

References (31)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48. (Pubitemid 43042900)
2. Cheong HS, et al. 2008. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur. J. Clin. Microbiol. Infect. Dis. 27:1219-1225.
3. Combes A, et al. 2006. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med. 32:1970-1978. (Pubitemid 44833110)
4. Drusano GL, et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760. (Pubitemid 47378891)
5. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. 2012. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit. Care Med. 40:1157-1163.
6. Falagas ME, Karageorgopoulos DE. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis. 46:1121-1122. (Pubitemid 351589881)
7. Joo EJ, et al. 2011. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb. Drug Resist. 17:305-312.
8. Joo EJ, et al. 2011. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection 39:309-318.
9. Kang CI, et al. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37:745-751.
10. Kang CI, et al. 2005. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb. Drug Resist. 11:68-74.
11. Kumar A. 2010. Early antimicrobial therapy in severe sepsis and septic shock. Curr. Infect. Dis. Rep. 12:336-344.
12. Kumar A, et al. 2009. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237-1248.
13. Kumar A, et al. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596. (Pubitemid 43810035)
14. Kumar A, Safdar N, Kethireddy S, Chateau D. 2010. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a metaanalytic/meta- regression study. Crit. Care Med. 38:1651-1664.
15. Kumar A, et al. 2010. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit. Care Med. 38:1773-1785.
16. Lautenbach E, et al. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31:47-53.
17. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. 2010. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:4939-4941.
18. Leibovici L, Vidal L, Paul M. 2009. Aminoglycoside drugs in clinical practice: an evidence-based approach. J. Antimicrob. Chemother. 63:246-251.
19. Lipovy B, et al. 2010. Prevalence and resistance of Pseudomonas aeruginosa in severely burned patients: a 10-year retrospective study. Acta Chir. Plast. 52:39-43.
20. McCabe W. 1962. Gram-negative bacteremia. I. Etiology and ecology. Arch. Intern. Med. 10:847-855.
21. Ortega M, et al. 2009. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J. Antimicrob. Chemother. 63:568-574.
22. Paul M, et al. 2010. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 65:2658-2665.
23. Paul M, Leibovici L. 2005. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect. Dis. 5:192-193.
24. Pena C, et al. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob. Agents Chemother. 56:1265-1272.
25. Raymond DP, et al. 2003. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit. Care Med. 31:1035-1041. (Pubitemid 36444410)
26. Retamar P, et al. 2012. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity scorebased analysis. Antimicrob. Agents Chemother. 56:472-478.
27. Schechner V, et al. 2011. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn. Microbiol. Infect. Dis. 71:38-45.
28. Tam VH, et al. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722.
29. Vidal F, et al. 1996. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch. Intern. Med. 156:2121-2126. (Pubitemid 26346971)
30. Vidal L, et al. 2007. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 60:247-257. (Pubitemid 47243870)
31. Wisplinghoff H, et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)